Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham (low certainty).
1 finding from 1 review
Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD
Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.
1 finding from 1 review
Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD
Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.
1 finding from 1 review
Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD
Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham (low certainty).
1 finding from 1 review
Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD
Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in loss of ≥ 15 letters BCVA at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in change in BCVA from baseline at 1 year (ETDRS letters) compared with sham (moderate certainty).
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review